Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1040b in Acute Ischemic Stroke
NCT02586233Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2015
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing DS-1040b with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 90 days. Started Sep 2015; status: completed.
02
Drugs
DS1040b
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02586233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586233.